Pfizer (PFE) Other Non-Current Assets (2009 - 2026)

Pfizer (PFE) has 18 years of Other Non-Current Assets data on file, last reported at $9.8 billion in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $9.8 billion, changed 0.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 billion (changed 0.11% YoY), and the FY2025 annual result was $9.6 billion, down 1.89% from the prior year.
• Other Non-Current Assets climbed to $9.8 billion in Q1 2026 per PFE's latest filing, from $9.6 billion in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $13.2 billion in Q4 2022 and troughed at $7.7 billion in Q3 2022.
• A 5-year average of $10.4 billion and a median of $9.8 billion in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 71.42% in 2022, then declined 21.28% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $13.2 billion in 2022, then declined by 5.26% to $12.5 billion in 2023, then fell by 21.28% to $9.8 billion in 2024, then fell by 1.89% to $9.6 billion in 2025, then grew by 2.11% to $9.8 billion in 2026.
• Business Quant data shows PFE's Other Non-Current Assets at $9.8 billion in Q1 2026, $9.6 billion in Q4 2025, and $9.3 billion in Q3 2025.